Department of Hemato-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
Department of Pediatric Hematology and Oncology, Erasmus Medical Center, Sophia Children's Hospital, Rotterdam, Netherlands.
Pathol Oncol Res. 2022 Aug 11;28:1610482. doi: 10.3389/pore.2022.1610482. eCollection 2022.
Immunohistochemical markers are associated with treatment outcome in adults with classical Hodgkin Lymphoma (cHL). Studies in children are scarce and inconsistent. We investigated in 67 children with cHL, whether the expression of CD15, CD30, PAX5, PD-1, PD-L1, CD68, CD163 and TARC at diagnosis is associated with disease free survival (DFS) and with interim remission status. Low CD15 and low TARC expression were associated with relapsed disease. Low expression of PD-L1 was associated with complete remission at interim PET-scan. Our data suggest a difference between pediatric and adult cHL. This underlines the importance of future research into specific prognostic factors in pediatric cHL, indispensable for improvement of treatment in this population.
免疫组织化学标志物与成人经典霍奇金淋巴瘤 (cHL) 的治疗结果相关。儿童的研究很少且不一致。我们在 67 例 cHL 患儿中研究了诊断时 CD15、CD30、PAX5、PD-1、PD-L1、CD68、CD163 和 TARC 的表达是否与无病生存 (DFS) 和中期缓解状态相关。低 CD15 和低 TARC 表达与疾病复发相关。PD-L1 低表达与中期 PET 扫描时完全缓解相关。我们的数据表明儿童 cHL 与成人 cHL 存在差异。这强调了未来在儿科 cHL 中研究特定预后因素的重要性,这对于改善该人群的治疗至关重要。